Android app on Google Play

Transcept (TSPT) Dismisses Action Against Watcon (WPI) Over Generic Intermezzo ANDA

December 26, 2012 6:23 AM EST Send to a Friend
As previously reported, on July 19, 2012, Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) received a Paragraph IV notice letter from Watson Laboratories, Inc. – Florida (NYSE: WPI), advising Transcept that Watson had filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for generic versions of Intermezzo (zolpidem tartrate) sublingual tablet C-IV. In response to Watson’s ANDA, on August 27, 2012, Transcept joined Purdue Pharma and Purdue Pharma L.P. (collectively, “Purdue”) in filing an action (the “Action”) against Watson, Watson Pharmaceuticals, Inc. and Watson Pharma, Inc.

On November 28, 2012, Watson withdrew its ANDA, and, as a result of such withdrawal, on December 18, 2012 Transcept and Purdue agreed to voluntarily dismiss the Action without prejudice and on December 20, 2012 a court order was entered to such effect. The dismissal of the Action has no effect on the ANDA filed by Actavis Elizabeth LLC, a wholly owned subsidiary of Watson Pharmaceuticals, Inc., which was reported by Transcept on July 19, 2012.




You May Also Be Interested In


Related Categories

Corporate News, FDA, Litigation

Add Your Comment